Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Neurotrophic Keratitis: full-pipeline trial registry

4 of 7 indexed Neurotrophic Keratitis trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Neurotrophic Keratitis: 7 US clinical trials tracked, 4 recruiting.

Neurotrophic Keratitis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Toyos Clinic, running 2 of these trials.

Enrollment posture brief

Registry condition neurotrophic-keratitis

OPEN 4 | RECR 57% | LATE 2 | EARLY 2 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Neurotrophic Keratitis (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Neurotrophic Keratitis

Neurotrophic Keratitis lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neurotrophic Keratitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neurotrophic Keratitis is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neurotrophic Keratitis research.

    Toyos Clinic accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Neurotrophic Keratitis trials plan to enrol fewer than 100 people.

    Median target enrolment is 12 among the 7 trials that report a genuine target (sentinel values excluded). 7 of those (100%) plan for fewer than 100 participants.

  4. Neurotrophic Keratitis splits between interventional and observational designs.

    4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 42

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 4 2

Named interventions

Most-linked intervention names on Neurotrophic Keratitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cenegermin Ophthalmic Solution [Oxervate] Drug
2 trials
Cenegemin in the DEFENDO Study Drug
1 trials
Acthar Gel 80 UNT/ML Injectable Solution Drug
1 trials
Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE] Drug
1 trials
BRM424 Ophthalmic Solution - Dose2 Drug
1 trials
BRM424 Ophthalmic Solution - Dose1 Drug
1 trials
KB801 Biological
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Neurotrophic Keratitis trials. A trial with sites in several states counts in each.

California 3 trials
Tennessee 2 trials
Pennsylvania 2 trials
New York 1 trials
New Jersey 1 trials
North Dakota 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neurotrophic Keratitis page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Neurotrophic Keratitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Toyos Clinic sponsors the most Neurotrophic Keratitis trials on record, review their full trial history before evaluating a specific study. See Toyos Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurotrophic Keratitis condition card totals 7 registered trials; most-linked intervention Cenegermin Ophthalmic Solution [Oxervate]; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.